Previous studies have demonstrated that CXCL12/CXCR4 axis is closely related to tumors such as malignant pleural mesothelioma (MPM). This research was conducted in order to detect whether CXCL12/CXCR4 inhibitors could restrain MPM and have a synergistic effect with chemotherapy, also to investigate the relationship of CXCL12/CXCR4 with other gene expressions in MPM. Forty mice were injected MPM cells and randomly divided into four groups: the PBS (control group), AMD3100 (CXCR4-CXCL12 antagonist), pemetrexed and AMD3100 plus pemetrexed. The mice were treated respectively for duration of 3 weeks. The size, bioluminescence and weight of tumors were measured. The differences between gene expressions in each group were analyzed. The tumor weights of each treatment group were lower than that of the control group (p<0.05). The bioluminescence of the tumor of the AMD3100 treatment group and the AMD3100 plus pemetrexed treatment group were lower than that of the control group (p<0.05), and AMD3100 was shown to have synergistic effects with pemetrexed (p<0.05). Among the 2.5 billion genes, several hundreds of genes expressed differently between groups. Results show that AMD3100 and pemetrexed can inhibit the growth of MPM in vivo, also that there is a better result if both are used together. Our findings suggest that CXCL12/CXCR4 axis affects a certain amount of gene expression in MPM.
RobinsonBW, LakeRA. Advances in malignant mesothelioma. N Engl J Med2005;353:1591–603.doi:10.1056/NEJMra050152
2.
RakeC, GilhamC, HatchJ, . Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer2009;100:1175–83.doi:10.1038/sj.bjc.6604879
3.
GilhamC, RakeC, BurdettG, . Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med2016;73:290–9.doi:10.1136/oemed-2015-103074
VogelzangNJ, RusthovenJJ, SymanowskiJ, . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol2003;21:2636–44.doi:10.1200/JCO.2003.11.136
6.
LiT, LiH, WangY, . The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol2011;223:519–30.doi:10.1002/path.2829
7.
XuC, HuaF, ChenY, . MTA1 promotes metastasis of MPM via suppression of E-cadherin. J Exp Clin Cancer Res2015;34:151.doi:10.1186/s13046-015-0269-8
8.
MiaoZ, LukerKE, SummersBC, . CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A2007;104:15735–40.doi:10.1073/pnas.0610444104
9.
HollandJD, GyörffyB, VogelR, . Combined Wnt/β-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep2013;5:1214–27.doi:10.1016/j.celrep.2013.11.001
10.
Conley-LaCombMK, SaligananA, KandagatlaP, . PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer2013;12:85–94.doi:10.1186/1476-4598-12-85
11.
IeranòC, SantagataS, NapolitanoM, . CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis2014;5:e1310–80.doi:10.1038/cddis.2014.269
12.
KuribayashiN, UchidaD, KinouchiM, . The role of metabotropic glutamate receptor 5 on the stromal cell-derived factor-1/CXCR4 system in oral cancer. PLoS One2013;8:e80773.doi:10.1371/journal.pone.0080773
13.
Réaux-Le GoazigoA, Van SteenwinckelJ, RostèneW, . Current status of chemokines in the adult CNS. Prog Neurobiol2013;104:67–92.doi:10.1016/j.pneurobio.2013.02.001
14.
Reaux-Le GoazigoA, RivatC, KitabgiP, . Cellular and subcellular localization of CXCL12 and CXCR4 in rat nociceptive structures: physiological relevance. Eur J Neurosci2012;36:2619–31.doi:10.1111/j.1460-9568.2012.08179.x
15.
MontresorA, ToffaliL, MirendaM, . JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia. Oncotarget2015;6:34245–57.doi:10.18632/oncotarget.5196
16.
MüllerA, HomeyB, SotoH, . Involvement of chemokine receptors in breast cancer metastasis. Nature2001;410:50–6.doi:10.1038/35065016
17.
KoizumiK, HojoS, AkashiT, . Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci2007;98:1652–8.doi:10.1111/j.1349-7006.2007.00606.x
18.
HendrixCW, FlexnerC, MacFarlandRT, . Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother2000;44:1667–73.doi:10.1128/AAC.44.6.1667-1673.2000
19.
DarbySC, EwertzM, McGaleP, . Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med2013;368:987–98.doi:10.1056/NEJMoa1209825
20.
DonzellaGA, ScholsD, LinSW, . AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med1998;4:72–7.doi:10.1038/nm0198-072
21.
De ClercqE. The bicyclam AMD3100 story. Nat Rev Drug Discov2003;2:581–7.doi:10.1038/nrd1134
22.
Ben-BaruchA. Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis2008;25:345–56.doi:10.1007/s10585-007-9097-3
23.
EbosJM, LeeCR, Cruz-MunozW, . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell2009;15:232–9.doi:10.1016/j.ccr.2009.01.021
24.
IshikawaT, NakashiroK, KlosekSK, . Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol Rep2009;21:707–12.
25.
MasuM, TanabeY, TsuchidaK, . Sequence and expression of a metabotropic glutamate receptor. Nature1991;349:760–5.doi:10.1038/349760a0
26.
BottaroDP, RubinJS, FalettoDL, . Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science1991;251:802–4.doi:10.1126/science.1846706
27.
JagadeeswaranR, MaPC, SeiwertTY, . Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res2006;66:352–61.doi:10.1158/0008-5472.CAN-04-4567
28.
LeeD, SungES, AhnJH, . Development of antibody-based c-Met inhibitors for targeted cancer therapy. Immunotargets Ther2015;4:35–44.doi:10.2147/ITT.S37409
29.
KantetiR, RiehmJJ, DhanasinghI, . PI3 kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma. Sci Rep2016;6:32992.doi:10.1038/srep32992
30.
PaselloG, UrsoL, MencoboniM, . MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. Oncotarget2015;6:42053–66.doi:10.18632/oncotarget.5974
31.
BalabanNQ, SchwarzUS, RivelineD, . Force and focal adhesion assembly: a close relationship studied using elastic micropatterned substrates. Nat Cell Biol2001;3:466–72.doi:10.1038/35074532
LuoDY, WazirR, TianY, . Integrin αv mediates contractility whereas integrin α4 regulates proliferation of human bladder smooth muscle cells via FAK pathway under physiological stretch. J Urol2013;190:1421–9.doi:10.1016/j.juro.2013.04.027
37.
LuuNT, GlenKE, EggintonS, . Integrin-substrate interactions underlying shear-induced inhibition of the inflammatory response of endothelial cells. Thromb Haemost2013;109:298–308.doi:10.1160/TH12-06-0400
38.
McLeanGW, CarragherNO, AvizienyteE, . The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer2005;5:505–15.doi:10.1038/nrc1647
39.
SekidoY. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci2010;101:1–6.doi:10.1111/j.1349-7006.2009.01336.x
40.
KrabLC, GoordenSM, ElgersmaY. Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases. Trends Genet2008;24:498–510.doi:10.1016/j.tig.2008.07.005
41.
ShuklaA, BarrettTF, MacPhersonMB, . An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol2011;45:906–14.doi:10.1165/rcmb.2010-0282OC
